The QMSR transition is not a compliance project. It is an operating-model reset.
Feb 2, 2026 is treated as a deadline. For most mid-market MedTech companies, it is actually the forcing function that exposes how brittle the last decade of QMS investment really was.
Most MedTech quality organizations have spent the last decade layering procedures on top of procedures. Each new audit finding, each new product line, each new regulation added another document. By 2024 the average mid-market QMS contained more surface area than any single person could hold in their head — and more exceptions than any auditor could reliably trace.
The FDA QMSR transition is not asking for more procedures. It is asking for the procedures to actually be traceable to ISO 13485:2016. This is a much harder ask than "write new SOPs." It requires remapping the entire procedure library against a new framework, identifying every orphaned document, and defending the mapping in an audit.
The firms treating this as a paperwork exercise will pass the first audit. The ones treating it as an operating-model reset — consolidating, deprecating, automating — will come out of 2026 with a QMS that actually scales. The rest will have bought themselves another decade of drift, more expensively.
The short version of our thesis: QMSR is a forcing function. Use it.